tng462
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 26, 2023 (NCT05732831)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
PRMT5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06922591 | Phase 1/Phase 2 (Phase 2) | May 31, 2025 | Revolution Medicines, Inc., Tango Therapeutics, Inc. |
| NCT05732831 | Phase 1/Phase 2 (Phase 2) | May 26, 2023 | Tango Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2023 |
| Revolution Medicines, Inc. | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1